modelBivalirudin

Diagram of Bivalirudin

Extends from Pharmacolibrary.Drugs.ATC.B.B01AE06.

Information

name:Bivalirudin
ATC code:B01AE06
route:intravenous
compartments:2
dosage:0.75mg
volume of distribution:0.2L
clearance:3.4mL/min/kg
other parameters in model implementation

Bivalirudin is a synthetic 20-amino acid polypeptide direct thrombin inhibitor used as an anticoagulant, mainly in the setting of percutaneous coronary intervention (PCI), and approved for use as an alternative to heparin, particularly in patients with or at risk for heparin-induced thrombocytopenia. It is approved by the FDA and used in current clinical practice.

Pharmacokinetics

Pharmacokinetics in adult patients undergoing percutaneous coronary intervention, both male and female, normal renal and hepatic function.

References

  1. Zhang, DM, et al., & Cui, YM (2012). Population pharmacokinetics and pharmacodynamics of bivalirudin in young healthy Chinese volunteers. Acta pharmacologica Sinica 33(11) 1387–1394. DOI:10.1038/aps.2012.37 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22659624

  2. Zhang, D, et al., & Cui, Y (2011). Pharmacokinetics, pharmacodynamics, tolerability and safety of single doses of bivalirudin in healthy chinese subjects. Biological & pharmaceutical bulletin 34(12) 1841–1848. DOI:10.1248/bpb.34.1841 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22130240

  3. Scandroglio, AM, et al., & Pappalardo, F (2021). Impact of CytoSorb on kinetics of vancomycin and bivalirudin in critically ill patients. Artificial organs 45(9) 1097–1103. DOI:10.1111/aor.13952 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33686696

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)